Gsk (GSK) Net Shares Issued and Repurchased (2025 - 2026)
Gsk (GSK) posted quarterly Net Shares Issued and Repurchased of -$439.5 million for Q1 2026, down 41.28% year-over-year from -$748.4 million in Q1 2025, and up 59.11% quarter-over-quarter from -$1.1 billion in Q4 2025.
Gsk (GSK) Net Shares Issued and Repurchased (2025 - 2026) Analysis & Trends
Gsk's Net Shares Issued and Repurchased history runs 2 years deep, the most recent figure standing at -$439.5 million for Q1 2026.
- In Q1 2026, Net Shares Issued and Repurchased fell 41.28% year-over-year to -$439.5 million; the TTM figure through Mar 2026 stood at -$9.1 billion (up 18.16% YoY), while the FY2025 annual figure was -$1.8 billion, changed N/A from the prior year.
- Net Shares Issued and Repurchased for Q1 2026 stood at -$439.5 million, up from -$1.1 billion in the prior quarter.
- The five-year high for Net Shares Issued and Repurchased was -$311.1 million in Q1 2025, with the low at -$1.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -439.51 Mn |
| Mar 31, 2026 | -439.51 Mn |
| Dec 31, 2025 | -1.07 Bn |
| Dec 31, 2025 | -1.07 Bn |
| Mar 31, 2025 | -311.10 Mn |
| Mar 31, 2025 | -311.10 Mn |